OncoMatch/Gastric / Stomach Cancer/PD-L1 (CD274)
Gastric / Stomach CancerPD-L1 (CD274) Clinical Trials
PD-L1 CPS guides selection and expected benefit for first-line chemoimmunotherapy in gastric and GEJ cancer; benefit is strongest at higher CPS, and current labels increasingly restrict use in PD-L1–negative disease. CPS thresholds vary by regimen and have been refined across label updates. Trials investigate novel checkpoint combinations, anti-VEGF plus IO regimens, and second-line IO strategies stratified by PD-L1 CPS.
Top recruiting PD-L1 (CD274) Gastric / Stomach Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
More PD-L1 (CD274) Gastric / Stomach Cancer trials
See all in search →17 international trials (no US sites)
Browse other molecular targets with active Gastric / Stomach Cancer trials.